118 related articles for article (PubMed ID: 26746574)
1. Emerging role of tumor markers and biochemistry in the preoperative invasive assessment of intraductal papillary mucinous neoplasm of the pancreas.
You L; Ma L; Zhao WJ; Zhao YP; Dai MH
Clin Chim Acta; 2016 Feb; 454():89-93. PubMed ID: 26746574
[TBL] [Abstract][Full Text] [Related]
2. Clinical implication of serum carcinoembryonic antigen and carbohydrate antigen 19-9 for the prediction of malignancy in intraductal papillary mucinous neoplasm of pancreas.
Kim JR; Jang JY; Kang MJ; Park T; Lee SY; Jung W; Chang J; Shin Y; Han Y; Kim SW
J Hepatobiliary Pancreat Sci; 2015 Sep; 22(9):699-707. PubMed ID: 26178866
[TBL] [Abstract][Full Text] [Related]
3. Role of serum carbohydrate antigen 19-9 and carcinoembryonic antigen in distinguishing between benign and invasive intraductal papillary mucinous neoplasm of the pancreas.
Fritz S; Hackert T; Hinz U; Hartwig W; Büchler MW; Werner J
Br J Surg; 2011 Jan; 98(1):104-10. PubMed ID: 20949535
[TBL] [Abstract][Full Text] [Related]
4. Inferior head resection of the pancreas for intraductal papillary mucinous neoplasms.
Nakagohri T; Kinoshita T; Konishi M; Takahashi S; Gotohda N; Kobayashi S; Kojima M; Miyauchi H; Asano T
J Hepatobiliary Pancreat Sci; 2010 Nov; 17(6):798-802. PubMed ID: 19727540
[TBL] [Abstract][Full Text] [Related]
5. Nonoperative management of main pancreatic duct-involved intraductal papillary mucinous neoplasm might be indicated in select patients.
Roch AM; DeWitt JM; Al-Haddad MA; Schmidt CM; Ceppa EP; House MG; Zyromski NJ; Nakeeb A; Schmidt CM
J Am Coll Surg; 2014 Jul; 219(1):122-9. PubMed ID: 24862887
[TBL] [Abstract][Full Text] [Related]
6. A comparison between intraductal papillary neoplasms of the biliary tract (BT-IPMNs) and intraductal papillary mucinous neoplasms of the pancreas (P-IPMNs) reveals distinct clinical manifestations and outcomes.
Minagawa N; Sato N; Mori Y; Tamura T; Higure A; Yamaguchi K
Eur J Surg Oncol; 2013 Jun; 39(6):554-8. PubMed ID: 23506840
[TBL] [Abstract][Full Text] [Related]
7. Preoperative evaluation of invasive and noninvasive intraductal papillary-mucinous neoplasms of the pancreas: clinical, radiological, and pathological analysis of 123 cases.
Nara S; Onaya H; Hiraoka N; Shimada K; Sano T; Sakamoto Y; Esaki M; Kosuge T
Pancreas; 2009 Jan; 38(1):8-16. PubMed ID: 18665010
[TBL] [Abstract][Full Text] [Related]
8. [The value of preoperative CA19-9 combined with platelet-to-lymphocyte ratio in predicting invasive malignancy in intraductal papillary mucinous neoplasms].
Li JA; Han X; Fang Y; Zhang L; Lou WH; Xu XF; Wu WC; Kuang TT; Wang DS; Rong YF
Zhonghua Wai Ke Za Zhi; 2019 Mar; 57(3):170-175. PubMed ID: 30861644
[No Abstract] [Full Text] [Related]
9. Serum Anti-p53 Antibody Can Serve as a Predictive Marker for Histological Grade of Intraductal Papillary Mucinous Neoplasms of the Pancreas.
Hata T; Mizuma M; Motoi F; Iseki M; Omori Y; Hayashi H; Nakagawa K; Morikawa T; Kamei T; Naitoh T; Furukawa T; Unno M
Pancreas; 2020 Jul; 49(6):768-773. PubMed ID: 32541631
[TBL] [Abstract][Full Text] [Related]
10. [Diagnostic efficacy for predicting intraductal papillary mucinous neoplasms of the pancreas with high grade dysplasia or invasive carcinoma based on the surgery indications in different guidelines].
Li B; Guo SW; Shi XH; Shen S; Zhang GX; Gao SZ; Pan YQ; Xu XF; Jin G
Zhonghua Wai Ke Za Zhi; 2021 May; 59(5):359-365. PubMed ID: 33915626
[No Abstract] [Full Text] [Related]
11. The natural history of main duct-involved, mixed-type intraductal papillary mucinous neoplasm: parameters predictive of progression.
Roch AM; Ceppa EP; Al-Haddad MA; DeWitt JM; House MG; Zyromski NJ; Nakeeb A; Schmidt CM
Ann Surg; 2014 Oct; 260(4):680-8; discussion 688-90. PubMed ID: 25203885
[TBL] [Abstract][Full Text] [Related]
12. Pancreatic Fluid Interleukin-1β Complements Prostaglandin E2 and Serum Carbohydrate Antigen 19-9 in Prediction of Intraductal Papillary Mucinous Neoplasm Dysplasia.
Simpson RE; Yip-Schneider MT; Flick KF; Wu H; Colgate CL; Schmidt CM
Pancreas; 2019 Sep; 48(8):1026-1031. PubMed ID: 31404023
[TBL] [Abstract][Full Text] [Related]
13. Long-term prospective cohort study of patients undergoing pancreatectomy for intraductal papillary mucinous neoplasm of the pancreas: implications for postoperative surveillance.
Kang MJ; Jang JY; Lee KB; Chang YR; Kwon W; Kim SW
Ann Surg; 2014 Aug; 260(2):356-63. PubMed ID: 24378847
[TBL] [Abstract][Full Text] [Related]
14. Plasma MicroRNAs as Novel Biomarkers for Patients with Intraductal Papillary Mucinous Neoplasms of the Pancreas.
Permuth-Wey J; Chen DT; Fulp WJ; Yoder SJ; Zhang Y; Georgeades C; Husain K; Centeno BA; Magliocco AM; Coppola D; Malafa M
Cancer Prev Res (Phila); 2015 Sep; 8(9):826-34. PubMed ID: 26314797
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathologic study of the MIB-1 labeling index (Ki67) and postoperative prognosis for intraductal papillary mucinous neoplasms and ordinary ductal adenocarcinoma.
Takeshita A; Kimura W; Hirai I; Takasu N; Moriya T; Tezuka K; Watanabe T
Pancreas; 2012 Jan; 41(1):114-20. PubMed ID: 22143341
[TBL] [Abstract][Full Text] [Related]
16. Updates and Critical Evaluation on Novel Biomarkers for the Malignant Progression of Intraductal Papillary Mucinous Neoplasms of the Pancreas.
Moris D; Damaskos C; Spartalis E; Papalampros A; Vernadakis S; Dimitroulis D; Griniatsos J; Felekouras E; Nikiteas N
Anticancer Res; 2017 May; 37(5):2185-2194. PubMed ID: 28476781
[TBL] [Abstract][Full Text] [Related]
17. Cyst fluid carcinoembryonic antigen level is not predictive of invasive cancer in patients with intraductal papillary mucinous neoplasm of the pancreas.
Kucera S; Centeno BA; Springett G; Malafa MP; Chen YA; Weber J; Klapman J
JOP; 2012 Jul; 13(4):409-13. PubMed ID: 22797397
[TBL] [Abstract][Full Text] [Related]
18. Predictors of malignant intraductal papillary mucinous neoplasm of the pancreas.
Mimura T; Masuda A; Matsumoto I; Shiomi H; Yoshida S; Sugimoto M; Sanuki T; Yoshida M; Fujita T; Kutsumi H; Ku Y; Azuma T
J Clin Gastroenterol; 2010 Oct; 44(9):e224-9. PubMed ID: 20453661
[TBL] [Abstract][Full Text] [Related]
19. Circulating Thrombospondin-2 enhances prediction of malignant intraductal papillary mucinous neoplasm.
Simpson RE; Yip-Schneider MT; Wu H; Fan H; Liu Z; Korc M; Zhang J; Schmidt CM
Am J Surg; 2019 Mar; 217(3):425-428. PubMed ID: 30293901
[TBL] [Abstract][Full Text] [Related]
20. Treatment strategy for intraductal papillary mucinous neoplasm of the pancreas based on malignant predictive factors.
Hirono S; Tani M; Kawai M; Ina S; Nishioka R; Miyazawa M; Fujita Y; Uchiyama K; Yamaue H
Arch Surg; 2009 Apr; 144(4):345-9; discussion 349-50. PubMed ID: 19380648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
